An Educational Opportunity for Clinicians Specializing in the Treatment of
Schizophrenia

Faculty

 

Leslie L. Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Disclosures

Indiana University School of Medicine requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CME/CE activity. Indiana University School of Medicine also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Indiana University School of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.

The following disclosure information has been provided.

Chair

Leslie L. Citrome, MD, MPH

Consulting Agreements/Advisory Board: Alexza Pharmaceuticals; Alkermes; Bristol-Myers Squibb Company; Eli Lilly and Company; EnVivo Pharmaceuticals; Forest Pharmaceuticals, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lundbeck; Merck & Co., Inc.; Mylan Inc.; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Reckitt Benckiser Group Plc.; Reviva Pharmaceuticals Inc.; Sunovion Pharmaceuticals, Inc.

Speakers’ Bureau: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited

Financial Interests/Stock Ownership: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Pfizer Inc.

Staff and Reviewer Disclosure

All Academy for Continued Healthcare Learning and Indiana University School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.